Drug name: Salinomycin + Imatinib Mesylate


Related CSCTT Targets

Kit-low/Cd44+/Cd34+ ICC stem cells [ref.1]

Salinomycin

Cas.no PubChem ID
53003-10-4 72370
Known Target
Structure
...
Introduction
Salinomycin is initially an antibacterial and coccidiostat ionophore therapeutic drug. Salinomycin has been shown by Piyush Gupta et al. of the Massachusetts Institute of Technology and the Broad Institute to kill breast cancer stem cells in mice at least 100 times more effectively than the anti-cancer drug paclitaxel. The mechanism of action by which salinomycin kills cancer stem cells specifically remains unknown, but is thought to be due to its action as a potassium ionophore due to the detection of nigericin in the same compound screen.

Imatinib Mesylate

Cas.no PubChem ID
220127-57-1 123596
Known Target
BCR/ABL fusion proteinA9UF02
Mast/stem cell growth factor receptor KitP10721
RET proto-oncogeneO43519
High affinity nerve growth factor receptorP04629
Macrophage colony-stimulating factor 1 receptorP07333
Platelet-derived growth factor receptor alphaP16234
Epithelial discoidin domain-containing receptor 1Q08345
Tyrosine-protein kinase ABL1P00519
Platelet-derived growth factor receptor betaP09619
Structure
...
Introduction
Imatinib is a small molecule kinase inhibitor used to treat certain types of cancer. It is currently marketed by Novartis as Gleevec (USA) or Glivec (Europe/Australia) as its mesylate salt, imatinib mesilate (INN). It is occasionally referred to as CGP57148B or STI571 (especially in older publications). It is used in treating chronic myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs) and a number of other malignancies.

Reference

  • [1] Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors. Bardsley, M. R., et al. (2010).Gastroenterology.139(3):942-52.
    20621681. [ 20621681 ]

Back to top